Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It?

J Arthroplasty. 2023 Jan;38(1):1-2. doi: 10.1016/j.arth.2022.09.017. Epub 2022 Nov 6.

Authors

Javad Parvizi¹, David E DeMik¹, William J Hozack¹, Michael J Dunbar², Michael A Mont³, Paul F Lachiewicz⁴

Affiliations

¹ Rothman Orthopaedic Institute, Philadelphia, Pennsylvania.
² Dalhousie University, Halifax, Nova Scotia, Canada.
³ Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland.
⁴ Duke University, Durham, North Carolina.

PMID: 36351554
DOI: 10.1016/j.arth.2022.09.017

No abstract available

Publication types

Editorial

MeSH terms

Anticoagulants / therapeutic use
Aspirin / therapeutic use
Heparin
Heparin, Low-Molecular-Weight* / therapeutic use
Humans
Thromboembolism* / etiology
Thromboembolism* / prevention & control

Substances

Heparin, Low-Molecular-Weight
Aspirin
Anticoagulants
Heparin